[氯替泼诺乙酯治疗干眼症的研究]

[Study on the treatment of dry eye with Loteprednol Etabonate].

作者信息

Wan Peng-xia, Wang Xiao-ran, Song Yi-yue, Li Zhao-yang, Duan Hu-cheng, Zhang Wei, Liu Zhao, Wang Zhi-chong

机构信息

Sun Yat-sen University, Guangzhou, China.

出版信息

Zhonghua Yan Ke Za Zhi. 2012 Feb;48(2):142-7.

PMID:22490950

Abstract

OBJECTIVE

To observe the efficacy and safety of 0.5% Loteprednol Etabonate ophthalmic suspension in the treatment of moderate dry eye.

METHODS

Totally 34 dry eye patients (68 eyes) in grade 2 or grade 3 (DEWS standard) enrolled in our hospital from March 2009 to September 2010 were randomly divided into two groups: the experimental group (Loteprednol Etabonate Group) and the control group (Cyclosporine A, CsA group). 0.5% Loteprednol Etabonate ophthalmic suspension or 1% CsA eye drops was applied 2 times a day respectively together with 0.2% Liposic eye drops (4 - 6 times/day). Questionnaire was used in these patients before the treatment and repeated every 2 weeks during the treatment till 8 weeks. Slit lamp microscope examination, fluorescent staining, tear break-up time (BUT), Schirmer I test (SIt) and intraocular pressure measurement were carried out at the same time point. The conjunctival impression cytology (IC) was performed before the treatment and 8 weeks after the treatment. The mean of the results were compared by t-tests and χ(2) test.

RESULTS

After 2 weeks of the treatment, the mean score of the questionnaire was significantly lower than that before the treatment in each group (t = 5.36, 3.63, P < 0.01). After 4 weeks of the treatment, the inflammation of the ocular surface was relieved obviously in both group and the mean score of the corneal fluorescein staining (FL) was lower than that before the treatment in each group. The average density of the goblet cells before the treatment was (181.2 ± 16.1)/mm(2) and (179.4 ± 17.5)/mm(2) in each group respectively. After 8 weeks of the treatment, this increased to (348.6 ± 22.5)/mm(2) and (360.4 ± 27.8)/mm(2) significantly (t = 16.9, 16.3, P < 0.05). BUT was significantly prolonged in each group after the treatment (P < 0.01). There was no significant change in ST I or NCT in each group (P > 0.05).

CONCLUSIONS

Topical 0.5% Loteprednol Etabonate ophthalmic suspension is safe and effective for the treatment of moderate dry eye.

摘要

目的

观察0.5%氯替泼诺妥布霉素眼用混悬液治疗中度干眼症的疗效及安全性。

方法

选取2009年3月至2010年9月我院收治的34例2级或3级（DEWS标准）干眼症患者（68只眼），随机分为两组：实验组（氯替泼诺组）和对照组（环孢素A组）。分别给予0.5%氯替泼诺妥布霉素眼用混悬液或1%环孢素A滴眼液，每日2次，同时联合0.2%立宝舒滴眼液（每日4 - 6次）。治疗前对患者进行问卷调查，治疗期间每2周重复一次，直至8周。在同一时间点进行裂隙灯显微镜检查、荧光素染色、泪膜破裂时间（BUT）、泪液分泌试验（SIt）及眼压测量。治疗前及治疗8周后进行结膜印迹细胞学检查（IC）。结果均值采用t检验和χ(2)检验进行比较。

结果

治疗2周后，两组患者问卷平均得分均显著低于治疗前（t = 5.36, 3.63, P < 0.01）。治疗4周后，两组患者眼表炎症均明显减轻，角膜荧光素染色（FL）平均得分均低于治疗前。治疗前两组杯状细胞平均密度分别为(181.2 ± 16.1)/mm(2)和(179.4 ± 17.5)/mm(2)。治疗8周后，显著增加至(348.6 ± 22.5)/mm(2)和(360.4 ± 27.8)/mm(2)（t = 16.9, 16.3, P < 0.05）。治疗后两组BUT均显著延长（P < 0.01）。两组SIt或NCT均无显著变化（P > 0.05）。